Stock Finding Its Footing and Climbing Higher: Nektar Therapeutics (NASDAQ:NKTR)


Traders bought 4,211 call options on the stock.

About 15.69M shares traded or 932.24% up from the average. The stock's price is 39.99 and their relative strength index (RSI) stands at 90.97. It improved, as 17 investors sold Nektar Therapeutics shares while 40 reduced holdings. The disclosure for this sale can be found here.

Among 2 analysts covering IRSA Inversiones (NYSE:IRS), 1 have Buy rating, 0 Sell and 1 Hold. $163,985 worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by ROBIN HOWARD W. Nicholson John had sold 3,146 shares worth $61,504. As of the last earnings report the EPS was $-0.71 with 157.47M shares now outstanding. Bank of Montreal Can now owns 6,395 shares of the biopharmaceutical company's stock valued at $110,000 after buying an additional 208 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of Nektar Therapeutics by 5.8% during the 3rd quarter. Short shares fell from 12,723,557 to 12,559,722 over that period. Louisiana State Employees Retirement System boosted its stake in Nektar Therapeutics by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company's stock valued at $41,812,000 after purchasing an additional 12,730 shares during the last quarter. Arizona State Retirement System increased its position in Nektar Therapeutics by 1.0% in the 2nd quarter.

Insider Trades for Nektar Therapeutics show that the latest trade was made on 7 Nov 2017 where Doberstein (Stephen K), the Officer completed a transaction type "Sell" in which 300000 shares were traded at a price of $30.09. Given the stock's recent action, it seemed like a good time to take a closer look at the company's recent data.

Nektar Therapeutics (NASDAQ NKTR) opened at $32.50 on Friday. For NKTR, the company now has $37.97 Million of cash on the books, which is offset by $2.48 Million current liabilities. Nektar Therapeutics has a 1 year low of $11.41 and a 1 year high of $33.67. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: and their article: "Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) Report First Data ..." published on November 13, 2017 as well as's news article titled: "New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate ..." with publication date: November 13, 2017. Susquehanna Intl Gru Llp reported 330,739 shares or 0% of all its holdings. The firm had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. After $0.37 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -191.89% negative EPS growth.

In a report issued on November 8, Mizuho Securities also assigned a Buy rating to the stock with a $30 price target. They issued a "buy" rating and a $31.00 price objective on the stock. HC Wainwright started coverage on Nektar Therapeutics in a research note on Monday, August 7th. The rating was maintained by William Blair with "Outperform" on Monday, June 26. Finally, Cowen and Company began coverage on Nektar Therapeutics in a report on Tuesday, November 7th. They issued a "buy" rating and a $35.00 target price for the company. Rice Hall James & Associates Llc who had been investing in Nektar Therapeutics for a number of months, seems to be bullish on the $5.12B market cap company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of "Buy" and an average price target of $28.64. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US and global copyright & trademark legislation.

Nektar Therapeutics is a biopharmaceutical firm that discovers and develops medicines in areas of high unmet medical need.